[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][=Branch1][C][=O][N][C][C][Branch2][#Branch2][C][C][Branch2][Ring1][Ring1][C][Branch1][=Branch1][O][C][Ring1][=Branch1][O][C][O][S][=Branch1][C][=O][=Branch1][C][=O][O][O][C][C][Branch2][#Branch1][=N][C][Branch2][#Branch1][Branch2][C][Branch1][N][C][Branch1][Ring2][O][Ring1][=Branch1][C][=Branch1][C][=O][O][O][C][C][Branch2][Branch1][O][C][Branch2][Ring2][=C][C][Branch1][=Branch2][C][Branch1][Ring2][O][Ring1][=Branch1][C][O][O][C][C][Branch2][Ring1][Ring2][C][Branch1][S][C][Branch1][N][C][Branch1][Ring2][O][Ring1][=Branch1][C][=Branch1][C][=O][O][O][O][O][S][=Branch1][C][=O][=Branch1][C][=O][O][O][S][=Branch1][C][=O][=Branch1][C][=O][O][N][S][=Branch1][C][=O][=Branch1][C][=O][O][O][O][S][=Branch1][C][=O][=Branch1][C][=O][O][O]"}, {"from": "gpt", "value": "The molecule is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding."}]